BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, Steinhart C. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther 2018;7:183-95. [PMID: 29761330 DOI: 10.1007/s40121-018-0201-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Nickel K, Halfpenny NJA, Snedecor SJ, Punekar YS. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infect Dis 2021;21:222. [PMID: 33637050 DOI: 10.1186/s12879-021-05850-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kitabi EN, Minzi OMS, Mugusi S, Sasi P, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E. Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. Sci Rep 2018;8:16316. [PMID: 30397233 DOI: 10.1038/s41598-018-34674-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tarasova O, Biziukova N, Kireev D, Lagunin A, Ivanov S, Filimonov D, Poroikov V. A Computational Approach for the Prediction of Treatment History and the Effectiveness or Failure of Antiretroviral Therapy. Int J Mol Sci 2020;21:E748. [PMID: 31979356 DOI: 10.3390/ijms21030748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
4 Cabrera-Rodríguez R, Pérez-Yanes S, Estévez-Herrera J, Márquez-Arce D, Cabrera C, Espert L, Blanco J, Valenzuela-Fernández A. The Interplay of HIV and Autophagy in Early Infection. Front Microbiol 2021;12:661446. [PMID: 33995324 DOI: 10.3389/fmicb.2021.661446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nkeh-Chungag BN, Engwa GA, Businge C, Mdondolo M, Pajaro Medina M, Goswami N. Assessment of the impact of HIV infection and anti-retroviral treatment on the cardiometabolic health of pregnant mothers and their offspring (ARTMOMSBABES). BMC Cardiovasc Disord 2021;21:322. [PMID: 34193034 DOI: 10.1186/s12872-021-02130-2] [Reference Citation Analysis]
6 Dominick L, Midgley N, Swart LM, Sprake D, Deshpande G, Laher I, Joseph D, Teer E, Essop MF. HIV-related cardiovascular diseases: the search for a unifying hypothesis. Am J Physiol Heart Circ Physiol 2020;318:H731-46. [PMID: 32083970 DOI: 10.1152/ajpheart.00549.2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
7 Dai L, Liu A, Zhang H, Wu H, Zhang T, Su B, Shao Y, Li J, Ye J, Scott SR, Mahajan SD, Schwartz SA, Yu H, Sun L. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. Curr HIV Res 2019;17:324-34. [PMID: 31654514 DOI: 10.2174/1570162X17666191025115508] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Do Kwon Y, Wang XE, Bender MF, Yang R, Li Y, McKee K, Rawi R, O'Dell S, Schneck NA, Shaddeau A, Zhang B, Arnold FJ, Connors M, Doria-Rose NA, Kwong PD, Lei QP. Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography. Antibodies (Basel) 2021;10:23. [PMID: 34200826 DOI: 10.3390/antib10020023] [Reference Citation Analysis]
9 Ciccullo A, Baldin G, Dusina A, Cossu MV, Lombardi F, Borghetti A, Capetti A, Di Giambenedetto S. Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice. AIDS Res Hum Retroviruses 2021;37:486-8. [PMID: 33587008 DOI: 10.1089/AID.2020.0276] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sabranski M, Erdbeer G, Sonntag I, Stoehr A, Horst HA, Plettenberg A, Lebherz L, Stellbrink HJ, Hoffmann C. Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy. AIDS Care 2021;33:453-61. [PMID: 32106695 DOI: 10.1080/09540121.2020.1733466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Schonhofer C, Yi J, Sciorillo A, Andrae-Marobela K, Cochrane A, Harris M, Brumme ZL, Brockman MA, Mounzer K, Hart C, Gyampoh K, Yuan Z, Montaner LJ, Tietjen I. Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency. Biochem Pharmacol 2021;186:114462. [PMID: 33577894 DOI: 10.1016/j.bcp.2021.114462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sadraeian M, da Cruz EF, Boyle RW, Bahou C, Chudasama V, Janini LMR, Diaz RS, Guimarães FEG. Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV. ACS Omega 2021;6:16524-34. [PMID: 34235324 DOI: 10.1021/acsomega.1c01721] [Reference Citation Analysis]
13 Himmel DM, Arnold E. Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV. Pharmaceuticals (Basel) 2020;13:E122. [PMID: 32545407 DOI: 10.3390/ph13060122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Barbier F, Mer M, Szychowiak P, Miller RF, Mariotte É, Galicier L, Bouadma L, Tattevin P, Azoulay É. Management of HIV-infected patients in the intensive care unit. Intensive Care Med 2020;46:329-42. [PMID: 32016535 DOI: 10.1007/s00134-020-05945-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
15 Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Erratum to: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2021:ciab801. [PMID: 34878522 DOI: 10.1093/cid/ciab801] [Reference Citation Analysis]
16 Casado JL, Monsalvo M, Fontecha M, Vizcarra P, Rodriguez MA, Vivancos MJ, Moreno S. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. HIV Res Clin Pract 2019;20:64-72. [PMID: 31303142 DOI: 10.1080/15284336.2019.1628460] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
17 Schwarze LI, Sonntag T, Wild S, Schmitz S, Uhde A, Fehse B. Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients. Gene Ther 2021. [PMID: 33867524 DOI: 10.1038/s41434-021-00259-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2020:ciaa1391. [PMID: 33225349 DOI: 10.1093/cid/ciaa1391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
19 Deme P, Rojas C, Slusher BS, Rais R, Afghah Z, Geiger JD, Haughey NJ. Bioenergetic adaptations to HIV infection. Could modulation of energy substrate utilization improve brain health in people living with HIV-1? Exp Neurol 2020;327:113181. [PMID: 31930991 DOI: 10.1016/j.expneurol.2020.113181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Ng'uni T, Chasara C, Ndhlovu ZM. Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. Front Immunol 2020;11:590780. [PMID: 33193428 DOI: 10.3389/fimmu.2020.590780] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Maitre T, Muret P, Blot M, Waldner A, Duong M, Si-Mohammed A, Chavanet P, Aho S, Piroth L. Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice. Curr HIV Res 2019;17:190-7. [PMID: 31490758 DOI: 10.2174/1570162X17666190903232053] [Reference Citation Analysis]
22 Dybul M, Attoye T, Baptiste S, Cherutich P, Dabis F, Deeks SG, Dieffenbach C, Doehle B, Goodenow MM, Jiang A, Kemps D, Lewin SR, Lumpkin MM, Mathae L, McCune JM, Ndung'u T, Nsubuga M, Peay HL, Pottage J, Warren M, Sikazwe I; Sunnylands 2019 Working Group. The case for an HIV cure and how to get there. Lancet HIV 2021;8:e51-8. [PMID: 33271124 DOI: 10.1016/S2352-3018(20)30232-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
23 Di Carlo D, Falasca F, Palermo E, Mezzaroma I, Fimiani C, Siccardi G, Celani L, Di Campli FM, d'Ettorre G, Antonelli G, Turriziani O. Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting. AIDS Res Hum Retroviruses 2021;37:478-85. [PMID: 33487130 DOI: 10.1089/AID.2020.0196] [Reference Citation Analysis]
24 López Aspiroz E, Cabrera Figueroa SE, Valverde Merino MP, Carracedo Álvarez Á. Individualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient. Clin Drug Investig 2019;39:1125-31. [PMID: 31401737 DOI: 10.1007/s40261-019-00829-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Liu H, Hu PW, Dubrulle J, Stossi F, Nikolai BC, Mancini MA, Rice AP. Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen. PLoS One 2021;16:e0244771. [PMID: 33914760 DOI: 10.1371/journal.pone.0244771] [Reference Citation Analysis]
26 Anderson SJ, Hsu CY, Ou HT, Ko NY, Yang CT, Lopes S. Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan. Value Health Reg Issues 2021;24:216-23. [PMID: 33857719 DOI: 10.1016/j.vhri.2020.11.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Murray MM, Lin J, Buros Stein A, Wilcox ML, Cottreau J, Postelnick M, Palella FJ. Relationship of polypharmacy to HIV RNA suppression in people aged ≥ 50 years living with HIV. HIV Med 2021;22:742-9. [PMID: 34077632 DOI: 10.1111/hiv.13122] [Reference Citation Analysis]
28 Schwarze LI, Głów D, Sonntag T, Uhde A, Fehse B. Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application. Gene Ther 2021. [PMID: 34112993 DOI: 10.1038/s41434-021-00271-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Rolle CP, Nguyen V, Patel K, Cruz D, DeJesus E, Hinestrosa F. Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. Medicine (Baltimore) 2021;100:e27330. [PMID: 34559154 DOI: 10.1097/MD.0000000000027330] [Reference Citation Analysis]
30 Kerrigan D, Sanchez Karver T, Muraleetharan O, Savage V, Mbwambo J, Donastorg Y, Likindikoki S, Perez M, Gomez H, Mantsios A, Murray M, Beckham SW, Davis W, Galai N, Barrington C. "A dream come true": Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLoS One 2020;15:e0234666. [PMID: 32530939 DOI: 10.1371/journal.pone.0234666] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
31 Sun L, Peng Y, Yu W, Zhang Y, Liang L, Song C, Hou J, Qiao Y, Wang Q, Chen J, Wu M, Zhang D, Li E, Han Z, Zhao Q, Jin X, Zhang B, Huang Z, Chai J, Wang JH, Chang J. Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. J Med Chem 2020;63:8554-66. [PMID: 32678592 DOI: 10.1021/acs.jmedchem.0c00940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Abo-Zeid Y, Williams GR, Touabi L, McLean GR. An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles. Int J Pharm 2020;589:119826. [PMID: 32871219 DOI: 10.1016/j.ijpharm.2020.119826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]